Back to search results

Study of NTB-928 for Relapsed/Refractory Ovarian Cancer

This study is testing a drug called NTB-928 given through an IV to adult women with ovarian cancer that has returned (relapsed) or stopped responding to previous treatments (refractory). The main goals are to find out what side effects NTB-928 might cause, how the body handles the drug, and if it shows early signs of fighting ovarian cancer. You may be able to join if you are 18 or older, have a confirmed diagnosis of certain types of ovarian cancer, and have already received standard treatments. The study aims to enroll 90 participants. The current status of the study is unclear.

Study design
This is an interventional study with a planned enrollment of 90 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for adverse events and serious adverse events for up to approximately 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07690189

Study of NTB-928 in R/R OC

Recruiting
PHASE1Ages 18+InterventionalTreatment
TeneoSeven, Inc.
~90 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:NTB-928

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of dose-limiting toxicities (DLTs) within the first cycle of treatment with NTB-928
Measured over Up to 35 days
+12 more outcomes measured

Conditions

Relapsed/Refractory Ovarian Carcinoma

Explore related trials

Malignant Ovarian NeoplasmOvarian CarcinosarcomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Low Grade Serous Adenocarcinoma

NCT07690189

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Start Ccbd, Llc

    Fort Worth, Texasno site contact published

    Recruiting

  • START Northwell, LLC

    Lake Success, New Yorkno site contact published

    Recruiting

  • The University of Alabama

    Birmingham, Alabamano site contact published

    Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraskano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Clinical Trial Information
[email protected]
510-392-0929
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged 18 years or older
Have a confirmed diagnosis of ovarian cancer, including high-grade serous, high-grade endometrioid, low-grade serous, or clear cell ovarian cancer, or carcinosarcoma of the ovary. Patients with mucinous carcinoma are not eligible.
Have relapsed or refractory ovarian cancer and have already received standard treatments known to provide benefit; participants are eligible if they have platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer (with clearly documented ineligibility for further platinum chemotherapy).
Are able to understand the study requirements and are willing to provide written informed consent
Are willing to use effective birth control during the study and for a period after the last dose of study treatment, if of childbearing potential

Exclusion

Have another active cancer that could interfere with assessment of this study treatment
Have received another investigational drug or certain cancer treatments within a recent period before starting this study
Are pregnant or breastfeeding

What this trial measures

  • Number of dose-limiting toxicities (DLTs) within the first cycle of treatment with NTB-928Up to 35 days
  • Number of participants with adverse events (AEs) and serious adverse events (SAEs), by severity and relatedness to NTB-928Up to approximately 3 years
  • Maximum plasma concentration (Cmax)Up to approximately 3 years
  • Time to Cmax (Tmax)Up to approximately 3 years
  • Area under the plasma concentration-time curve (AUC) over the dosing interval (AUC0-T)Up to approximately 3 years
  • AUC from time zero to time t (AUC0-t)Up to approximately 3 years
  • AUC from time 0 extrapolated to infinity (AUC0-∞)Up to approximately 3 years
  • Terminal elimination half-life (t½)Up to approximately 3 years
  • Clearance (CL)Up to approximately 3 years
  • Terminal elimination rate constant (λz)Up to approximately 3 years
  • Volume of distribution (Vz)Up to approximately 3 years
  • Accumulation ratio (Rac) for Cmax and AUC, and trough concentration (Ctrough)Up to approximately 3 years
  • Number of participants with anti-drug antibodies (ADA) at baseline and after treatmentUp to approximately 3 years